Rational drug design of antineoplastic agents using 3D-QSAR, cheminformatic, and virtual screening approaches by Vucicevic, Jelica et al.
Rational drug design of antineoplastic agents 
1 
 
Rational drug design of antineoplastic agents using 3D-QSAR, cheminformatic, and 
virtual screening approaches 
 
Jelica Vucicevic1, Katarina Nikolic*1, and John B.O. Mitchell*2 
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, 
Vojvode Stepe 450, 11000 Belgrade, Serbia 
2EaStCHEM School of Chemistry and Biomedical Sciences Research Complex, University of 
St Andrews, St Andrews KY16 9ST, UK 
 
Corresponding Authors: 
Katarina Nikolic, PhD 
Assistant Professor 
Department of Pharmaceutical Chemistry 
Faculty of Pharmacy, University of Belgrade 
Vojvode Stepe 450, 11000 Belgrade, Serbia 
e-mail: knikolic@pharmacy.bg.ac.rs 
tel: +381-11-3951-259 
cell: +381-63-84-30-677 
 
Dr John B. O. Mitchell, 
EaStCHEM School of Chemistry and Biomedical Sciences Research Complex, 
University of St Andrews, 
North Haugh, 
St Andrews, 
Scotland, 
KY16 9ST. 
United Kingdom. 
e-mail: jbom@st-andrews.ac.uk 
+44-(0)1334-467259 
  
Rational drug design of antineoplastic agents 
2 
 
Abstract 
Background: Computer-Aided Drug Design has strongly accelerated the development of 
novel antineoplastic agents by helping in the hit identification, optimization, and evaluation. 
Results: Computational approaches such as cheminformatic search, virtual screening, 
pharmacophore modeling, molecular docking and dynamics have been developed and applied 
to explain the activity of bioactive molecules, design novel agents, increase the success rate 
of drug research, and decrease the total costs of drug discovery. Similarity searches and 
virtual screening are used to identify molecules with an increased probability to interact with 
drug targets of interest, while the other computational approaches are applied for the design 
and evaluation of molecules with enhanced activity and improved safety profile. Conclusion: 
In this review are described the main in silico techniques used in rational drug design of 
antineoplastic agents and presented optimal combinations of computational methods for 
design of more efficient antineoplastic drugs. 
Keywords: antineoplastic agents; pharmacophore; QSAR; rational drug design; 
cheminformatics; virtual screening; virtual docking 
Introduction 
Since cancer is a leading cause of death worldwide, discovery of novel, more potent 
antineoplastic agents is one of the most important and active drug discovery fields [1,2]. Even 
though drug research is a challenging, time consuming and expensive process, the number of 
compounds available to consider in the lead discovery stages of the drug discovery pipeline 
has significantly increased due to cheminformatics and Computer-Aided Drug Design 
(CADD) methodologies. In silico drug design mainly involves ligand-based methods, such as 
Quantitative Structure Activity Relationship (QSAR), Ligand-Based Pharmacophore 
Modeling, and structure-based methods, such as Virtual Docking (VD), Structure-Based 
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Pharmacophore Modeling, and Molecular Dynamics (MD) [3]. It is now widely accepted that 
rational drug design provides essential molecular understanding of drug-target interactions 
that is not easily and completely accessible from experimental techniques. Application of the 
in silico techniques has had a great impact on the efficient discovery of novel drug candidates 
[4-7].  Structure-based drug design requires the three-dimensional-structure of target or 
ligand-target complex to have been previously obtained by crystallography, Nuclear Magnetic 
Resonance (NMR) spectroscopy, or homology modeling. These 3D-structures are used as 
templates for performing virtual screening and virtual docking. Such structure-based studies 
have been employed for selection of molecular determinants for ligands binding and rational 
drug design. Finally, MD simulations of ligand-target complexes have been used to analyze 
the target structure conformations and to evaluate the affinity and stability of ligand-target 
complexes.  
The 3D-structures of ligand-target complexes have been employed for identifying structural 
origins of selectivity and chemical scaffolds of novel ligands as drug candidates with 
improved efficacy and safety profiles. In the rational drug design of antineoplastic agents, 
these structure-based methodologies are very useful and powerful tools in the early phases of 
the drug discovery process [8]. However, ligand-based drug design methods, which provide 
information about essential structural characteristics for biological activity based on the 
ligands alone, have also shown themselves to be efficient techniques for the identification of 
potential lead structures, and some have argued that they are more efficient than methods 
based on target protein structures [9]. A recently developed method that combines structure 
and pharmacophore activity relationship studies into a single drug-target interaction 
evaluation represents an exciting novel approach in drug discovery [10]. Finally, combination 
of results obtained from ligand-based and structure-based virtual screening and integrated 
Rational drug design of antineoplastic agents 
4 
 
with virtual docking and QSAR data has been claimed to be the most comprehensive rational 
drug discovery procedure with the highest success rate [10-13]. 
This review will describe and discuss some of the most recent investigations in which these 
in silico tools were used for the optimization and rational design of novel antineoplastic 
drugs. 
 
QSAR studies in the rational design of antineoplastic drugs 
 
QSAR methods have been widely applied in medicinal chemistry in order to gain insight into 
the critical structural requirements for compounds to interact with the biomolecules of 
interest. This computational tool uses information from molecular structures of ligands, 
correlates this with corresponding activities by employing different mathematical algorithms, 
determines the most important structural features controlling the bioactivity, and facilitates 
their application for design of novel drug candidates with enhanced activity on the drug target 
[11-13]. Furthermore, pharmacophores selected in QSAR studies can be used as search 
queries to screen the databases, leading to the identification of novel potential antineoplastic 
drugs [14-16]. Such QSAR models can predict the bioactivities of novel designed compounds 
and prioritize them for in vitro evaluation. 
In order to increase the interpretability and reduce the risk of overfitting, 3D-QSAR models 
are usually built by using only a few descriptors [17]. Those commonly used include 
topological indices (TIs), geometrical, constitutional and physicochemical descriptors. 
Constitutional descriptors including number of atoms, bond count, atom type counts, ring 
count, and molecular weight (MW) are simple features that reflect the molecular 
composition. TIs are 2D descriptors which encode information about molecular size, shape, 
degree of branching, presence of heteroatoms and multiple bonds [18]. They include Wiener 
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index [19], Connectivity indices [20], Kier shape [21], Balaban J index [22] and Zagreb 
indices [23]. Physicochemical descriptors are also usually computed simply from 2D 
molecular structure. However, 3D geometrical descriptors require information obtainable 
only from 3D structures of molecules, and thus are conformation dependent and require some 
form of geometry optimization (e.g. WHIM, MoRSE and GETAWAY, etc.) [24]. 
Historically, QSAR methodologies used quite simple mathematical methods such as linear 
and multi-linear regression, to describe and derive that relationship between the descriptors 
and the property to be predicted. In recent years, Partial Least Squares (PLS) [25] and 
Multiple Linear Regression (MLR) are the most common techniques applied to examine 
linear correlations between molecular descriptors and corresponding activity against targets 
of interest [26-32]. However, in many cases there is no such linear relationship between 
molecular determinants and bioactivity, and for that reason a range of more sophisticated 
machine learning methods have been introduced to computational chemistry [33]. While the 
ultimate advantage of such methods is their ability to generate more accurate predictive 
models, this is often achieved through their flexibility in representing non-linear relationships 
and often in handling relatively large descriptor sets. Many machine-learning techniques 
including Support Vector Machines (SVM), Artificial Neural Network (ANN), k-Nearest 
Neighbors (k-NN), Random Forest (RF) and genetic algorithms have been applied for better 
exploration of the bioactive chemical space of examined compounds. For example, Singh et 
al. [34] used RF to build a QSAR model for EGFR inhibitors. Beyond the QSAR domain, RF 
is also useful for other tasks in the drug discovery process; Riddick et al. [35] used RF to 
assess which cancer cell lines were likely to respond to which drugs, while Statnikov et al. 
[36] classified different types of cancer, and Carlsson et al. [37] used both RF and SVM to 
assess the mutagenicity of compounds. 
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One of the first 3D-QSAR methodologies was based on electrostatic interaction energies of 
superimposed 3D-conformations of a data set of ligands that are effectively included in 
Comparative Molecular Field Analysis (CoMFA) [38] or Comparative Molecular Similarity 
Index Analysis (CoMSIA) [39]. The main limitation of the approach is that dynamical 
properties of the examined compounds could not be included in the calculation [40]. On the 
other hand, the Molecular Interaction Field (MIF) methodology considers conformations of 
multiple ligands for determining Grid-Independent Descriptors (GRID) and pharmacophores 
in 3D-QSAR modeling [41,42]. The GRIDs are used as independent variables for 3D-QSAR 
modeling, pharmacophore study, and drug design [43-45]. Some very promising novel 
rational drug discovery methodologies have been developed as combinations of 3D-QSAR 
modeling and complementary drug target fields [46-49].  
Over the past few years, several advanced computer-aided drug design studies have been 
carried out on a number of epigenetic targets, such as histone arginine methyltransferases, 
histone deacetylase, and Hsp90 heat shock protein, by use of extensive molecular docking 
programs combined with 3D-QSAR [50,51] and comparative binding energy [49,52]. These 
in silico approaches were used to understand the activity of known ligands of epigenetic 
targets and to design novel epigenetic inhibitors. Epigenetic enzymes modulate expression of 
particular genes and regulate dynamic changes of histone proteins [53], DNA [54], RNA [55] 
and non-coding RNA [56]. Therefore, the enzymes associated with epigenetics, such as DNA 
methyltransferases (DNMT) [57], histone deacetylases (HDAC) [58], bromodomains [59], 
lysine demethylases [60], and lysine methyltransferases [61], are now considered to be very 
important anticancer drug targets [6]. Over the past few years, a significant increase in 
inhibitors of histone and non-histone proteins has successfully translated into clinical study 
[6]. 
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The human HDACs are divided into eleven isoforms (HDAC 1-11) [62,63]. Several 
pharmacological studies have confirmed that HDAC isoform selective inhibitors could have 
broader and safer clinical applications than pan-HDAC inhibitors. Recently determined 
crystal structures of several HDAC isoforms in complex with inhibitors [64,65] will 
significantly facilitate structure-based drug design of selective HDAC inhibitors and provide 
important information for understanding the enzymes’ functions [5,64]. Both 2D- and 3D-
QSAR approaches have been very useful in the design of novel HDAC inhibitors with 
enhanced potency and isoform selectivity. The developed QSAR models were employed to 
identify HDAC pharmacophores, optimize HDAC inhibitors and evaluate the inhibitory 
potency of the novel designed inhibitors [7,66,67]. The CoMFA and CoMSIA 3D-QSAR 
methodology has been used for development of novel HDAC inhibitors [68-72]. Also, a MIF-
based 3D-QSAR approach has been applied on four structurally diverse types of HDAC 
inhibitors [73]. Combination of the 3D-QSAR modeling and virtual docking has successfully 
identified compound ZINC70450932 as a novel inhibitor of HDAC1 [7] (Figure 1). 
Developed 3D-QSAR pharmacophore models were used to identify structural requirements 
for inhibitors binding to the HDAC enzyme [74,75], while Choubey et al. [7] developed a 
pharmacophore model of histone deacetylase 1 (HDAC1) inhibitors with two hydrogen bond 
acceptors, one hydrogen bond donor and one aromatic ring, employing 38 structurally diverse 
inhibitors. HDAC1 has been found to have a crucial role in multiple types of cancers.  Also, 
the electronic structure-activity relationship model, developed by use of an electronic 
structure-based algorithm, was applied for defining the inhibitory mechanism of the 
oligodeoxynucleotide DNMT1 inhibitors [76]. 
Numerous successful cases of 3D-QSAR studies being used in antineoplastic drug discovery 
have been reported so far. For example, this approach has been applied in the discovery of 
new Bcl-2 inhibitors [77], Bcl-xl inhibitors [78], mTOR inhibitors [79], and CDK1 inhibitors 
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[29] (Table 1). Actually, most modelling studies for identification of inhibitors of the Bcl-2 
family of proteins are based on structure-based methodologies [80-84]. Bcl-2 inhibitors 
exhibit potent anticancer activity against breast cancer cells (MDA-231) and leukemia cells 
(HL-60) which overexpress Bcl-2 protein [85,86]. Several QSAR models have also been 
developed for this class of inhibitors [77,78,87] . Almerico and coworkers [78] developed a 
3D-QSAR pharmacophore model of Bcl-xl inhibitors from the set of 42 
biarylacylsulfonamides. This model was used to identify the structural factors, including an 
aromatic moiety, negative charge and hydrogen bond acceptor, that govern the activity of 
these derivatives. Then the model was used as a 3D search query to screen the ZINC database 
and six hits with new scaffolds were identified (ZINC00784464, ZINC00788197, 
ZINC03200686, ZINC03212331, ZINC03243504, ZINC03356310) (Figure 1) [78]. 
Recently, Aboalhija et al. performed QSAR analysis to explore the structural features 
important for Bcl-2 inhibitory activity within a large and potent list of 98 inhibitors. Genetic 
function algorithm (GFA) coupled with k nearest neighbor (kNN) or multiple linear 
regression (MLR) analysis was applied to generate the best predictive QSAR models. The 
resulting QSAR-selected pharmacophores were used as in silico search queries to screen the 
National Cancer Institute (NCI) database and several hits that exhibit low micromolar 
cytotoxic activity against MDA-MB-231 were identified [77]. The same procedure and 
methodology were used for identification of new nanomolar mTOR inhibitors [79].  
Nowadays, drug resistance is one of the major problems in cancer therapy. This obstacle 
could be overcome by using a combination of drugs with different mechanisms or by 
designing a single chemical entity that simultaneously modulates several targets [88,89]. As a 
result, development of agents able to interact with more than one biological target for cancer 
treatment is an interesting new concept in cancer drug design [6]. The first multi-target (mt) 
approach for the virtual screening has been published for anti-colorectal cancer (anti-CRC) 
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and anti-breast cancer (anti-BC) agents [90,91]. In this study, its authors designed more 
efficient anti-CRC and anti-BC drugs against ten and thirteen cell lines, respectively, by using 
multi-target QSAR and virtual screening techniques. The mt-QSAR models were developed 
by use of linear discriminant analysis (mt-QSAR-LDA). By analyzing these models, it was 
possible to identify substructural features responsible for the anticancer activity and thus to 
design novel potent and versatile agents.   
 
Virtual Screening and Virtual Docking methods 
 
Ligand- based virtual screening operates on the hypothesis that molecules with similar values 
of molecular descriptors should possess similar biological activity [92-95], the so-called 
similar property principle. This approach analyses the structural and physicochemical 
similarities between one or more lead compounds and large virtual library of plausible 
molecular structures, which need not yet actually have been synthesised, while structure-
based virtual screening is based on direct modelling of ligands binding to the 3D structure of 
the drug target.  Scores obtained by either or both virtual screening methodologies are then 
used to rank the examined ligands and to select novel hit compounds for further chemical 
modifications and testing [9].  
Ligand- or structure-based pharmacophore screening on compound databases compares each 
query molecule with the previously defined spatially located pharmacophore features, such as 
hydrogen-bond donor, hydrogen-bond acceptor, hydrophobic interactions, steric interactions, 
aromatic interactions, and positive and negative ionizable regions. Pharmacophore screening 
algorithms typically use overlay-based scoring functions and root-mean-square deviation for 
final ranking of hit compounds [96]. Pharmacophore screening has been successfully applied 
in the search for novel epigenetic inhibitors, such as selective HDAC inhibitors [97,98] and 
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inhibitors of protein arginine methyltransferases (PRMTs) [99]. Various combinations of 
ligand and structure-based virtual screening permit very comprehensive study of various 
aspects of drug action and therefore have higher hit success rates [3,14,100,101]. In 
particular, parallel [102,103] and hybrid [95,104] virtual screening approaches have been 
promoted as very precise rational drug design methodologies. 
Molecular docking is widely used as a rational drug design tool for protein-ligand complex 
modelling, indeed nowadays docking studies are considered an essential structure-based drug 
design strategy [105,106]. Docking into a known binding site of a single target protein can be 
an affordable and efficient computational technique which allows us to study the ligands’ 
interactions with targets and to estimate the potential energy of the protein–ligand complexes. 
A relatively simple and quick-to-evaluate objective function is generally used for the many 
calculations required to search the various possible conformations and positions of ligands in 
the binding site of the target and to optimize the 3D docked ligand-protein complex 
structures. However, more elaborate and expensive scoring functions may be used for the 
relatively few further calculations then required to rank these conformations and to select 
those corresponding to the strongest binding between the ligand and the target. Using these 
more sophisticated scoring functions, top ranked conformations of each ligand are compared 
and used for final ranking of all ligands in the data set [107]. The scoring functions used for 
the final ranking can be derived by a variety of approaches. One is to design a function which 
has separate empirical energy terms corresponding to different physicochemical contributions 
to binding, often including van der Waals, electrostatic, hydrogen bonding, steric, and 
desolvation terms, each described by a suitable parametric functional form [108].  While the 
resulting scoring function is thus expressed as a sum of apparently meaningful components, 
only the total interaction free energy is actually fitted to real data in most cases and hence 
there is cancellation of error between terms and the interpretability of the individual 
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components is obscured. A second approach is to base each of the contributing interactions on 
the corresponding term in a molecular mechanics force field [109]. A third possibility is to 
derive a statistically based scoring function from analysis of the crystal structures, and in 
some versions also the binding energies, of known ligand-protein complexes [110]. Thus, the 
molecular docking approach provides insight into the binding mode of the ligand and target, 
compares different ligands, and estimates their binding energies. The objective and scoring 
functions used in docking reflect the fact that binding of a ligand to its target is partly based 
on their chemical complementarities and physicochemical interactions, and partly on shape 
complementarities, which may well be conformation-dependent. Flexibility of the target 
biomolecule can be modelled either by performing virtual docking to set of rigid protein 
conformations or by examining dynamic ligand-target complexes [111].  
Several structure-based virtual screening studies have recently been performed on epigenetic 
targets using some of the most popular molecular docking programs, such as DOCK [112], 
AutoDock [113,114], GOLD [115], and Glide [116]. These investigations resulted in the 
discovery of selective and potent inhibitors of histone arginine methyltransferases [117,118], 
bromodomain (BRD) type 4 inhibitors [119,120] and DNA methyltransferases type 1 
[121,122]. This methodology also found new scaffolds that can be used for experimental 
optimization or as a starting point for chemical space exploration. 
Successful applications such as development of Bcl-2xL agents [80], topoisomerase I and II 
inhibitors [123], COX-2/5-LOX dual inhibitors [124], Rac1 agents [125], inhibitors of Hsp90 
[126], inhibitors of Tip 60 [127], mTOR [128], histone deacetylase inhibitors [129], hTERT 
inhibitors [130,131] and CDK [29] agents highlight the importance of this virtual docking 
technique (Table 2). These, like many other targets involved in cellular events such as cell 
growth, differentiation and proliferation, could serve as potential targets for drug discovery 
directed towards various types of cancer. Since the topoisomerases are essential enzymes 
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involved in various cell processes, their inhibition is one of the most important mechanisms 
of anticancer drugs. Ashour et al. [123]  designed analogues of oleanolic acid with enhanced 
activity against topoisomerase I and IIα inhibition based on information obtained from active 
sites using docking techniques (based on PDB structures 1t8i and 1bgw for topoisomerase I 
and IIα, respectively) [132,133]. Ten designed compounds with good docking scores and 
promising binding modes were synthesized, and five of them (known as S2, S3, S5, S7 and 
S9) showed greater inhibitory activity against topoisomerase I than did the reference 
molecule camptothecin (CPT). Also, it was found that S2, S3, S5 and S6 showed greater 
topoisomerase II inhibitory activity than etoposide. Four compounds (S2, S3, S5 and S7) act 
as dual inhibitors of both enzymes, therefore potentially having an important role in cancer 
prevention (Figure 2) [123]. Based on structure-based drug design, several series of 
compounds, including N-substituted-dihydropyrazoles, dihydropyrazole-coumarin and 
myricetin, were designed and synthesized as potential human telomerase inhibitors. The 
binding mode of these compounds was explored in docking studies which provide 
information that supports rational design of more efficient telomerase inhibitors [130,131]. 
Apart from providing an insight into the binding mode of the ligands to their target, docking 
techniques are widely used in virtual screening studies of large databases. An example of this 
rational design approach was published by Cardama and coworkers [125]. Rac1, a member of 
Rho family of small GTPases, appears to be a promising and relevant target for the 
development of novel anticancer drugs since it is overexpressed in breast, colorectal, gastric, 
testicular, lung and brain cancer [134-137]. Docking-based virtual library screening was 
conducted on the ZINC database considering the portion of the Rac1 surface area containing 
a critical Trp56 as the target (PDB ID code 1MH1), and the Rac1 inhibitor ZINC69391 was 
identified. It was shown that ZINC69391 exerts an antimetastatic effect in vivo. A novel 
analog of this compound (1A-116) with a high docking score was developed by rational 
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design and it has proved to be more specific and potent at lower doses than its parent 
compound, both in vivo and in vitro (Figure 3). These results show that these novel Rac1 
inhibitors, developed by docking techniques, have a good prospect of being useful as novel 
agents in anticancer therapy. 
Several docking and molecular dynamic studies on epigenetic targets have recently been 
performed and resulted in the discovery of more selective and potent inhibitors of HDAC 
[138-141], bromodomain [119,120,142], DNMT [143-145], the histone methyltransferases 
(HMT) and the histone acetyltransferases (HAT) [146]. The results of these in silico studies 
are very helpful for defining the reaction mechanisms and identifying the key interactions  
between known active ligands and their epigenetic targets. 
 
Target Prediction 
 
Earlier, we discussed drugs that can interact with more than one target [88,89]. This may on 
occasion give rise to polypharmacology, beneficial pharmacological effects from a drug 
inhibiting or modulating multiple protein targets [147]. Another application of multi-target 
ligands is drug repurposing, where drugs are redirected from one originally intended 
therapeutic area to another [148]. If computational predictions can identify previously 
unrecognized drug-target associations, then drug repurposing may progress from serendipity 
and trial-and-error to being a more mature evidence-based science, and more frequently and 
reliably deliver significant health benefits to patients. 
Too frequently, off-target interactions result in adverse side-effects, which it is important both 
to understand and to predict [149]. In recent years, such off-target drug interactions with 
unexpected proteins have led to a significant number of serious adverse drug reactions 
(ADRs). This has affected both compounds in development, many of which fail to reach the 
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market due to these unforeseen side-effects, and also marketed drugs whose safety and 
viability can be seriously compromised in this way [150], and may have to be withdrawn 
from sale. Both patients and pharmaceutical companies suffer when such withdrawals are 
required. 
The development of multiple target prediction techniques requires the existence of copious 
molecule-target assay data, incorporating a good range of both ligands and targets. Various 
experimental technologies, such as target and phenotype based assay, are currently employed 
to find the underlying macromolecular targets involved in complex biological mechanisms 
[151]. 
Typically, target prediction methods work via molecular similarity. For a given target, the set 
of molecules experimentally known to bind to it are encoded using descriptors, and used as 
training data to build up a profile of what a ligand of this protein typically looks like. In some 
cases, such binders may form two or more quite separate clusters, possibly corresponding to 
different ligand scaffolds or to different binding sites. Given that most molecules have not 
been publicly assayed against most targets, this matrix of training data is sparse and careful 
interpolation is required. While the problem may be mathematically formulated in different 
ways [147,152-155], its essence is to use descriptor-based molecular similarity to estimate the 
probability that a query compound belongs to the set of binders for the given target. 
Helpfully, Gfeller et al.  [156] have made their SwissTargetPrediction server publicly 
available. Where a model makes explicit use of known binding constants to predict 
quantitative binding affinities for putative compound-target pairs, the method is termed 
proteochemometric [147,157]. 
Another, rather computationally expensive, approach to the same problem is to dock a library 
of ligands into a panel of protein targets in silico. Glen and Allen [158] discussed the 
application of multiple dockings to cancer research, whilst when Favia et al.  [159] carried 
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out a study of this kind, their main purpose was protein function prediction as they aimed to 
identify the native substrates of enzymes. As various authors [152,160] have pointed out, 
however, the same cross-docking method could be used for multi-target and off-target 
prediction, provided that the scoring function was accurate enough to compare dockings into 
diverse protein structures. Meeting this criterion might be problematic, as Warren et al. [107] 
found no correlation between experimental binding affinities and calculated docking scores 
for a small but diverse set of targets. Nonetheless, the relative success achieved by 
Schomburg et al. [161] indicates that target prediction by docking is becoming 
computationally and methodologically tractable. 
Emig et al. [162] have used a target prediction approach to consider both drug repositioning 
and potential novel targets for cancer along with a number of other diseases. They consider 
the relationships between the pathological processes involved in different cancers such as 
hepatocellular carcinoma, colon cancer, ovarian cancer, thyroid cancer, melanoma, and acute 
myeloid leukemia. They suggest that there is a common core of cancer drug targets relevant 
to each of these diseases. Nigsch and Mitchell [163] carried out a target prediction study in 
which they algorithmically grouped together a diverse panel of protein targets according to 
their associated toxic effects.  They found that proteins associated with breast cancer, along 
with those linked to side effects of breast cancer drugs, clustered together.  
 
Conclusion 
 
Rational drug design has become essential methodology in discovery of antineoplastic agents. 
The pharmacophore and QSAR approaches employ the chemical structures of experimentally 
confirmed anticancer compounds to define molecular determinants for activity and use these 
results to design and evaluate novel molecules. Cheminformatic and virtual screening tools 
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have been used to rank the designed compounds and to identify new lead structures by 
searching in various databases. 
The 3D-structures of specific drug targets provide essential information for performing 
structure based virtual screening, molecular docking and dynamic studies. Based on these 
analyses have been filtered and ranked compounds from large databases, explained binding 
mode and activity of known ligands, and evaluated the conformational changes and stability 
of the ligand-target complexes. 
Further development of computer-aided drug design approaches, along with improvement in 
crystallographic and biological methods, will provide deeper knowledge of drug-target 
interactions and augment discovery of more efficient and safer anticancer drugs.  
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Figures 
Figure 1. Antineoplastic agents selected by using QSAR technique  
Figure 2. Analogues of oleanolic acid with enhanced activity against topoisomerase I and IIα 
inhibition 
Figure 3. ZINC69391 compound and its derived novel analog 1A-116 
  
Rational drug design of antineoplastic agents 
34 
 
 
Table 1. Reported QSAR studies used in rational drug design of antineoplastic agents 
Drug target Methodology Software package References 
B-cell lymphoma 2 (Bcl-2) family 
of proteins 
3D-QSAR 
Virtual Screening 
DiscoveryStudio, version 2.2.5, Biovia Inc. 
(www.biovia.com) 
MATLAB, version 7.4.0.287- R2007a, 
MathWorks Inc. (www. mathworks.com) 
[77] 
B-cell lymphoma 2 extra-large 
(Bcl-2xl) family of proteins 
3D-QSAR 
Virtual Screening 
Molecular Docking 
PHASE, version 2.5, Schrödinger, LLC 
(www.schrodinger.com) 
Glide, version 4.5., Schrödinger LLC 
(www.schrodinger.com) 
[78] 
Mammalian target of rapamycin 
(mTOR) 
Pharmacophore 
modelling 
3D-QSAR 
CATALYST, Accelrys Software Inc. 
(www.accelrys.com) 
Discovery Studio, version 2.55, Biovia Inc. 
(www.biovia.com) 
[79] 
Cyclin-dependent kinase 1 
(CDK1) 
Pharmacophore 
modelling 
3D-QSAR 
Virtual Screening 
CATALYST, version 4.11,  Accelrys Software 
Inc. (www.accelrys.com) 
CERIUS2, version 4.10, Accelrys Software 
Inc. (www.accelrys.com) 
[29] 
13 breast cancer cell lines mt-QSAR 
LDA modules of StatSoft. STATISTICA, 
version 6.0 (www.statsoft.com) 
[90] 
10 colorectal cancer cell lines mt-QSAR 
LDA modules of StatSoft. STATISTICA, 
version 6.0 (www.statsoft.com) 
[91] 
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Table 2. Reported structure-based studies used in rational design of antineoplastic agents 
Drug target Methodology Software package References 
B-cell lymphoma extra- large 
(Bcl-xL) family of proteins 
Molecular Docking 
GOLD, version 5.1, CCDC 
(www.ccdc.cam.ac.uk) 
AutoDock Vina (vina.scripps.edu) 
[80] 
Topoisomerase I and II 
Molecular Docking 
Virtual Screening 
 
Molegro Virtual Docker (MVD) 
 (molegro-virtual-
docker.software.informer.com) 
GOLD, version 4.1 and 5.0, CCDC 
(www.ccdc.cam.ac.uk) 
[123] 
Cyclooxygenase-2 and 5-
lipoxygenase 
Molecular Docking AutoDock Vina, (vina.scripps.edu) [124] 
Rac1-GEF 
Molecular Docking 
Virtual Screening 
Autodock4 program 
eHITS, SimBioSys Inc. (www.simbiosys.ca) 
[125] 
Hsp90 Molecular Docking 
Surflex Geom X, Sybyl X-1.2 version  
(sybyl-x.software.informer.com) 
[126] 
Tip60 histone acetyltransferases 
Molecular Docking 
Molecular 
Dinamics 
Molecular Operating Environment (MOE), 
version 2010.10, Chemical computing group 
Inc. (www.chemcomp.com) 
YASARA, version 10.7.20 (www.yasara.org) 
[127] 
Mammalian target of rapamycin 
(mTOR) 
Pharmacophore 
modeling 
Molecular 
Docking/Virtual 
Screening 
CATALYST, Accelrys Software Inc. 
(www.accelrys.com) 
LigandFit docking engine 
[128] 
Histone deacetylase (HDAC) Molecular Docking 
Molecular Operating Environment (MOE), 
Chemical computing group Inc. 
(www.chemcomp.com) 
[129] 
Human telomerase reverse 
transcriptase (hTERT) and 
tetrahymena telomerase p65 
Molecular Docking 
Molecular 
Dynamics 
Glide, version 5.9, Schrödinger, LLC 
(www.schrodinger.com) 
Desmond, Schrödinger, LLC 
(www.schrodinger.com) 
[130] 
Human telomerase reverse 
transcriptase (hTERT) 
Molecular Docking 
Molecular 
Dynamics 
Glide, Schrödinger, LLC 
(www.schrodinger.com) 
Desmond, Schrödinger, LLC 
(www.schrodinger.com) 
[131] 
 
